# A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

> **NCT07031700** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Relapsed/Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07031700
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07031700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07031700, "A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT07031700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*